Effect of Shock Wave Therapy Without Biological and Immuno-histochemical Analysis.

NACompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

January 7, 2018

Primary Completion Date

March 28, 2019

Study Completion Date

October 28, 2019

Conditions
Obesity
Interventions
DEVICE

shock wave therapy

The participants received the treatment protocol established by the manufacturer of the Thork Shock Wave® device, IBRAMED- Industria Brasileira de Equipamentos Electromédicos, Amparo, São Paulo approved by Anvisa No. 10360310036. (Figure 1). The parameters were, 4,000 thousand shots with energy of 180mJ and frequency of 15Hz with 15mm stainless steel tip and 2,000 shots with energy of 100mJ and frequency of 15Hz with 15mm plastic tip, and for the tip slip, Neutral Thork® Lotion, RMC was used. Seven ESWT sessions were held, the average time of each was seven minutes, twice a week and the seventh session was held minutes before the surgical procedure of bariatric surgery, therapy was performed in an area of 150cm² on the left side of the abdominal region following the midline. The right side of the participants' abdomen did not receive ESWT and was termed as control.

Trial Locations (1)

13083-872

Unicamp, Campinas

All Listed Sponsors
lead

Indústria Brasileira Equipamentos Médicos - IBRAMED

INDUSTRY

NCT05017636 - Effect of Shock Wave Therapy Without Biological and Immuno-histochemical Analysis. | Biotech Hunter | Biotech Hunter